AM-Pharma

AM-Pharma is a clinical-stage biopharmaceutical company developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase, as an enzyme replacement therapy. The treatment targets adult patients with hypophosphatasia (HPP), a rare genetic metabolic disorder that causes impaired bone mineralization, muscle weakness, and chronic pain. The company's lead compound is engineered to restore enzymatic activity and reduce disease-related biomarkers through subcutaneous administration.